Attached files
file | filename |
---|---|
8-K - FORM 8-K - AYTU BIOPHARMA, INC | v476415_8k.htm |
Exhibit 99.1
Aytu BioScience, Inc. | ||||||
Proforma Balance Sheet | ||||||
June 30, 2017 | ||||||
Unaudited |
6/30/2017 | Pro Forma | Pro Forma | ||||||||||
Consolidated | Adjustments (a) | Combined (b) | ||||||||||
Assets | ||||||||||||
Current assets | ||||||||||||
Cash and cash equivalents | $ | 802,328 | $ | 10,637,752 | $ | 11,440,080 | ||||||
Restricted cash | 75,214 | 75,214 | ||||||||||
Accounts receivable, net | 528,039 | - | 528,039 | |||||||||
Inventory, net | 1,312,221 | - | 1,312,221 | |||||||||
Prepaid expenses and other | 310,760 | - | 310,760 | |||||||||
Total current assets | 3,028,562 | 10,637,752 | 13,666,314 | |||||||||
Fixed assets, net | 647,254 | - | 647,254 | |||||||||
Developed technology, net | 1,337,333 | - | 1,337,333 | |||||||||
Customer contracts, net | 77,667 | - | 77,667 | |||||||||
Trade names, net | 164,037 | - | 164,037 | |||||||||
Natesto asset | 9,231,072 | - | 9,231,072 | |||||||||
Goodwill | 238,426 | - | 238,426 | |||||||||
Patents, net | 271,278 | - | 271,278 | |||||||||
Deposits | 2,888 | - | 2,888 | |||||||||
Total long-term assets | 11,969,955 | - | 11,969,955 | |||||||||
Total assets | $ | 14,998,517 | $ | 10,637,752 | $ | 25,636,269 | ||||||
Liabilities and Stockholders' Equity | ||||||||||||
Current liabilities | ||||||||||||
Accounts payable and other | $ | 2,220,400 | $ | - | $ | 2,220,400 | ||||||
Accrued liabilities | 782,536 | - | 782,536 | |||||||||
Accrued compensation | 339,704 | - | 339,704 | |||||||||
Deferred rent | 6,673 | - | 6,673 | |||||||||
Contingent consideration | 261,155 | - | 261,155 | |||||||||
Warrant derivative liability | - | 3,323,411 | 3,323,411 | |||||||||
Total current liabilities | 3,610,468 | 3,323,411 | 6,933,879 | |||||||||
Contingent consideration | 7,386,782 | - | 7,386,782 | |||||||||
Deferred rent | 1,451 | - | 1,451 | |||||||||
Total liabilities | 10,998,701 | 3,323,411 | 14,322,112 | |||||||||
Commitments and contingencies | ||||||||||||
Stockholders' equity | ||||||||||||
Preferred Stock, par value $.0001; 50,000,000 shares authorized; none issued | - | 1 | 1 | |||||||||
Common Stock, par value $.0001; 100,000,000 shares authorized; shares issued | ||||||||||||
and outstanding 824,831 in 2017 and 187,098 in 2016 | 82 | 320 | 402 | |||||||||
Additional paid-in capital | 73,069,463 | 7,314,020 | 80,383,483 | |||||||||
Accumulated deficit | (69,069,729 | ) | - | (69,069,729 | ) | |||||||
Total stockholders' equity | 3,999,816 | 7,314,341 | 11,314,157 | |||||||||
- | ||||||||||||
Total liabilities and stockholders' equity | $ | 14,998,517 | $ | 10,637,752 | $ | 25,636,269 |
(a) | These are the adjustments to account for the $11.8M financing transaction on 8/15/17 |
(b) | This is the proforma Balance sheet as if the $11.8M financing had happened on 6/30/17 |